World Meningitis Day
Meningitis affects 1 million people globally each year. The disease, which can kill a person in 24 hours, is caused by inflammation of the brain and spinal cord. Many types of bacteria, and some viruses and fungi, cause meningitis. Some types can be prevented with safe and effective vaccines; others cannot. The organizers of World Meningitis Day (April 24) plan to highlight the many causes of meningitis. The ASBMB is observing the day by sharing articles on various meningitis-causing pathogens.
Cryptococcal meningitis is responsible for an estimated 15 percent of all AIDS-related deaths. Antifungals, which some immunocompromised patients must take for life to prevent meningitis, often target biosynthetic pathways including lipid biogenesis. A recent study in the Journal of Lipid Research undertook a comprehensive catalogue of lipids in various strains of Cryptococcus and described a number of possible future antifungal targets. Read the work here.
A paper in the Journal of Biological Chemistry described the structure of an enzyme called ADS lyase from Cryptococcus neoformans, which may be another antifungal drug target. Read the article here.
Herpes viruses can induce meningitis. An article in Molecular & Cellular Proteomics introduced a database of protein-protein interactions within herpesvirus-1. The database predicted some hitherto unknown interactions within the virus, and may in the future be used to organize proteomics findings and identify new drug targets. Access the open-access article here or the database here.
Viral meningitis sometimes arises as a fatal complication of hand, foot and mouth disease caused by enterovirus 71. A paper in the Journal of Biological Chemistry described an unexpected mechanism by which the virus blocks cell signaling to circumvent the immune system’s antiviral response. Read more here.
Vaccination against Neisseria meningitidis, a leading cause of bacterial meningitis, can be costly because researchers must grow the bacterium in culture to isolate oligosaccharide antigens. An article in the Journal of Biological Chemistry reports the development of enzyme-based tools to make oligosaccharides in vitro, which could someday lower the cost of vaccine production.
Trafficking of N. meningitidis lipoproteins to the outer bacterial membrane determines which antigens are available for immune recognition. A paper in Molecular & Cellular Proteomics investigated how N. meningitidis and other Gram-negative bacteria transport these proteins. Read the paper here.
Enterococcus faecalis is a commensal organism in the gastrointestinal tract, but can form dangerous biofilms on implanted medical devices that can lead to complications like bacterial meningitis. A paper in Molecular & Cellular Proteomics identified markers of biofilm formation ability that might help develop drugs to target biofilm formation and prevent infection.
Bacteria from the birth canal can be associated with life-threatening meningitis in newborns. Fortunately for infants, oligosaccharides from human milk can protect them from the same neonatal pathogens. A paper in the Journal of Biological Chemistry, accessible here, isolated the human milk oligosaccharide responsible for the protective effect.
Microglia are immune cells in the brain that respond to bacterial meningitis by launching an inflammatory response. A paper in the Journal of Biological Chemistry reported changes in microglial iron transport in response to activation. Find out more here.
The cause of meningitis is sometimes diagnosed by measuring the amount of protein in a spinal tap to find out whether the blood-brain barrier is intact. An article in the Journal of Lipid Research showed that disruption of the barrier raises the level of oxysterol 7-HOCA, along with protein, in the cerebrospinal fluid. Therefore, 7-HOCA could serve as a secondary diagnostic marker for bacterial meningitis and related conditions. Read more here.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.
In the inaugural JBC Methods Madness Tournament, cryo–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% — a margin thinner than shaved ice.
Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.